Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAeSTro-TSH: TSH Suppression in Active Surveillance for Thyroid Cancer
NCT06971965Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of levothyroxine sodium in Papillary Thyroid Carcinoma (PTC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Rate of Disease progression at 5 years. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT06971965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971965.